Aptevo Therapeutics (APVO) Invested Capital (2016 - 2025)
Aptevo Therapeutics (APVO) has disclosed Invested Capital for 11 consecutive years, with $17.4 million as the latest value for Q3 2025.
- Quarterly Invested Capital rose 293.48% to $17.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $17.4 million through Sep 2025, up 293.48% year-over-year, with the annual reading at $4.8 million for FY2024, 61.09% down from the prior year.
- Invested Capital hit $17.4 million in Q3 2025 for Aptevo Therapeutics, up from $6.5 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $25.0 million in Q2 2022 to a low of -$3.9 million in Q1 2022.
- Historically, Invested Capital has averaged $12.8 million across 5 years, with a median of $14.7 million in 2023.
- Biggest five-year swings in Invested Capital: soared 738.28% in 2021 and later plummeted 124.14% in 2025.
- Year by year, Invested Capital stood at $12.9 million in 2021, then surged by 55.04% to $20.0 million in 2022, then crashed by 38.82% to $12.2 million in 2023, then tumbled by 61.09% to $4.8 million in 2024, then surged by 265.76% to $17.4 million in 2025.
- Business Quant data shows Invested Capital for APVO at $17.4 million in Q3 2025, $6.5 million in Q2 2025, and -$1.5 million in Q1 2025.